Evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections have seen a significant increase over the past 20 years.
• These infections span a spectrum from skin and skin structure infections (cSSSI) to severe conditions like pneumonia and endocarditis.

Purpose of the Study:

• To review current and emerging antimicrobial therapies for CA-MRSA infections.
• To highlight the factors influencing antibiotic selection in clinical practice.

Main Methods:

• Literature review of antimicrobial agents and treatment guidelines for CA-MRSA.
• Analysis of resistance patterns, efficacy, and adverse effects of various antibiotics.

Main Results:

• Oral agents like trimethoprim-sulfamethoxazole, clindamycin, tetracyclines, and linezolid are options for uncomplicated cutaneous CA-MRSA infections alongside incision and drainage.
• Vancomycin is the standard for complicated, inpatient CA-MRSA infections, but resistance and reduced efficacy are concerns.
• Intravenous alternatives include linezolid, quinupristin/dalfopristin, daptomycin, and tigecycline.
• Investigational drugs such as dalbavancin, telavancin, oritivancin, iclaprim, ceftobiprole, and ceftaroline show promise for future treatment.

Conclusions:

• The choice of antibiotic for CA-MRSA infections requires careful consideration of resistance, patient factors, and infection severity.
• While established treatments exist, ongoing research into new antimicrobial agents is crucial to combat evolving CA-MRSA resistance and improve patient outcomes.